Mark M Perry1, Ian M Adcock, Kian Fan Chung. 1. Airways Disease, National Heart and Lung Institute, Imperial College, London and Royal Brompton NIHR Biomedical Research Unit, London, UK.
Abstract
PURPOSE OF REVIEW: MicroRNAs (miRNAs) modulate gene transcription in response to environmental stressors and other stimuli. A role for miRNAs in inflammation and immunity has been demonstrated and further evidence suggests that miRNAs also play a role in allergic asthma. RECENT FINDINGS: Studies investigating the differential expression of miRNAs in biological fluids between asthma patients and controls have been published, as have their role in immune cell subsets. Further development of miRNAs in therapy has been addressed. miRNA-146a has been implicated in autoimmunity and allergic inflammation and miRNA-155 in the development of atopy. Targeting of miRNA-1 and miRNA-145 has been used to inhibit lung inflammation in mouse models of asthma. Although these recent findings need to be confirmed, miRNAs may prove to be useful as potential biomarkers of disease. However, their use as therapeutic targets in the lung remains unclear. SUMMARY: There may be a potential role for using circulating miRNAs as biomarkers of disease status or response to therapy. The use of miRNAs as asthma therapy remains to be determined.
PURPOSE OF REVIEW: MicroRNAs (miRNAs) modulate gene transcription in response to environmental stressors and other stimuli. A role for miRNAs in inflammation and immunity has been demonstrated and further evidence suggests that miRNAs also play a role in allergic asthma. RECENT FINDINGS: Studies investigating the differential expression of miRNAs in biological fluids between asthma patients and controls have been published, as have their role in immune cell subsets. Further development of miRNAs in therapy has been addressed. miRNA-146a has been implicated in autoimmunity and allergic inflammation and miRNA-155 in the development of atopy. Targeting of miRNA-1 and miRNA-145 has been used to inhibit lung inflammation in mouse models of asthma. Although these recent findings need to be confirmed, miRNAs may prove to be useful as potential biomarkers of disease. However, their use as therapeutic targets in the lung remains unclear. SUMMARY: There may be a potential role for using circulating miRNAs as biomarkers of disease status or response to therapy. The use of miRNAs as asthma therapy remains to be determined.
Authors: Friederike Schaub; Werner Adler; Meike C Koenig; Philip Enders; Rafael S Grajewski; Claus Cursiefen; Ludwig M Heindl Journal: Graefes Arch Clin Exp Ophthalmol Date: 2016-08-24 Impact factor: 3.117
Authors: José M Rodrigo-Muñoz; Marta Gil-Martínez; Clara Lorente-Sorolla; Raquel García-Latorre; Marcela Valverde-Monge; Santiago Quirce; Joaquín Sastre; Victoria Del Pozo Journal: Front Immunol Date: 2022-04-01 Impact factor: 8.786
Authors: Lawrence O'Leary; Kenan Sevinç; Ilektra M Papazoglou; Bernadett Tildy; Karen Detillieux; Andrew J Halayko; Kian Fan Chung; Mark M Perry Journal: FEBS Lett Date: 2016-04-19 Impact factor: 4.124
Authors: Mitchell C Lock; Kimberley J Botting; Ross L Tellam; Doug Brooks; Janna L Morrison Journal: Int J Mol Sci Date: 2017-12-06 Impact factor: 5.923